Ladarixin Uses, Dosage, Side Effects and more
Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).
Trade Name | Ladarixin |
Generic | Ladarixin |
Ladarixin Other Names | Ladarixin |
Type | |
Formula | C11H12F3NO6S2 |
Weight | Average: 375.33 Monoisotopic: 375.005813947 |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |